GlassScriptPhysician profile
Eric Thomas Feduska
NPI 1801234117
$696.20
in general payments reported to CMS, 2019-2025
11 companies · $170 in 2025
The $170 reported for 2025 was more than what 77% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $20.09 · 2021: $141 · 2022: $78.90 · 2023: $132 · 2024: $48.31 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $349.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $151.98 | 2025 | Hemosphere |
| Abiomed | $129.09 | 2021-2024 | |
| Edwards Lifesciences Corporation | $104.85 | 2023 | Hemosphere |
| Atricure, INC. | $97.03 | 2022-2025 | Atricure Cryoice Cryoablation System (Cryo2) |
| Celgene Corporation | $90.32 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.53 | 2024 | Lifevest |
| Chiesi USA, INC. | $21.56 | 2021 | |
| Portola Pharmaceuticals, LLC | $20.09 | 2020 | |
| Masimo Corporation | $16.09 | 2019 | |
| Getinge USA Sales, LLC | $13.87 | 2023 | Vasoview Hemopro 2 |
| La Jolla Pharmaceutical Company | $12.79 | 2023 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Feduska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.